eBook: Empowering Antibody Discovery
Last updated: March 2023
Overview
Antibodies are ideal therapeutic candidates due to their ability to bind to a variety of targets with high affinity and specificity. Innovations in hybridoma and phage display technologies have allowed drug developers to exploit the natural diversity in antibodies, leading to the wide use of monoclonal antibodies (mAbs) in treating cancers, chronic inflammation, and infectious diseases.
In this eBook you can explore the rise of antibody therapeutics. Discover the tools and technologies empowering antibody discovery and take a deeper look into how kinetic live-cell analysis is transforming mAb screening workflows.
- Document type: eBook
- Page count: 46
- Read time: 30 minutes
Download the eBook to learn more:
- Functional characterization of mAbs using kinetic live-cell analysis
- Pharmacological characterization of an ADC using live-cell analysis
- Use of a real-time 96-well antibody internalization assay
- The benefits of using advanced flow cytometry and live-cell analysis for antibody profiling
eBook Sample: Explore quantification of ADCC in multi-spheroid models with the Incucyte® Live-Cell Analysis System enabling long term imaging
Figure 6. Quantification of Trastuzumab Driven ADCC Using an Advanced Cell Multi-Spheroid Model. Impact of trastuzumab[1]induced PBMCs on MS proliferation. (A) Incucyte® brightfield and fluorescence images taken at seven days (MCF-7) or ten days (BT-474) show the effect on spheroid proliferation in the absence (top panel) and presence (bottom panel) of PMBCs. The brightfield outline mask is shown in yellow.
